Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives

The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway

(2020) David E. Elder et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

The TERT copy number gain is sensitive to telomerase inhibitors in human melanoma

(2020) Jinyu Yu et al.   CLINICAL SCIENCE

Spitz melanoma is a distinct subset of spitzoid melanoma

(2020) Shyam S. Raghavan et al.   MODERN PATHOLOGY

The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research

(2020) Corrie A. Painter et al.   NATURE MEDICINE

Primary dermal melanoma: clinical behaviour, prognosis and treatment

(2020) Christopher G. Harris et al.   EJSO

Overall survival and biomarker analysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

(2020) Xinan Sheng et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study of vorolanib (CM082) in combination with toripalimab (JS001) in patients with advanced mucosal melanoma.

(2020) Lu Si et al.   JOURNAL OF CLINICAL ONCOLOGY

Preliminary activity of tipifarnib in tumors of the head and neck, salivary gland and urothelial tract with HRAS mutations.

(2020) Alan Loh Ho et al.   JOURNAL OF CLINICAL ONCOLOGY

NOMINATOR: Feasibility of genomic testing of rare cancers to match cancer to treatment.

(2020) Damien Kee et al.   JOURNAL OF CLINICAL ONCOLOGY

CheckMate 067: Long-term outcomes in patients with mucosal melanoma.

(2020) Alexander Noor Shoushtari et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary malignant melanoma of the lung: a case report and literature review

(2020) Shuangshuang Deng et al.   BMC Pulmonary Medicine

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma

(2019) Inês Pires da Silva et al.   CLINICAL CANCER RESEARCH

Differential modulation and prognostic values of immune-escape genes in uveal melanoma

(2019) Maria Sofia Basile et al.   PLoS One

Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas

(2019) Camelia Quek et al.   Oncotarget

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Brian I. Rini et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the ERK Signaling Pathway in Melanoma

(2019) Paola Savoia et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population‐based study

(2019) D Verver et al.   INTERNATIONAL JOURNAL OF CANCER

Analysis of mucosal melanoma whole-genome landscapes reveals clinically relevant genomic aberrations

(2019) Rong Zhou et al.   CLINICAL CANCER RESEARCH

Enhanced fatty acid scavenging and glycerophospholipid metabolism accompanies melanocyte neoplasia progression in zebrafish

(2019) Fiona Henderson et al.   CANCER RESEARCH

Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.

(2019) Tae Won Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing

(2019) Parvez M. Lokhandwala et al.   BMC CANCER

Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma

(2019) Antoine Moya-Plana et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma

(2019) Luz Dary Gutiérrez-Castañeda et al.   MELANOMA RESEARCH

The clinical characteristics of melanoma with BRAF V600R mutation

(2019) Karen A. Malkhasyan et al.   MELANOMA RESEARCH

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

(2019) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)

(2019) Lu Si et al.   Translational Oncology

Clinicopathological characteristics and survival of primary malignant melanoma of the esophagus

(2019) Tadayoshi Hashimoto et al.   Oncology Letters

Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets

(2019) Felicity Newell et al.   Nature Communications

Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?

(2019) Florian Castet et al.   Cancers

So Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UM Cure 2020

(2019) Manuel Rodrigues et al.   Cancers

Atypical BRAF and NRAS Mutations in Mucosal Melanoma

(2019) Nicolas Dumaz et al.   Cancers

Primary diffuse meningeal melanomatosis – a rare form of meningeal melanoma: case report

(2019) Tomasz Garbacz et al.   BMC Neurology

Esophageal melanoma: a systematic review and exploratory recurrence and survival analysis

(2019) D Schizas et al.   DISEASES OF THE ESOPHAGUS

Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations

(2019) Christian Menzer et al.   JOURNAL OF CLINICAL ONCOLOGY

The mutational landscape of mucosal melanoma

(2019) Kelsey W. Nassar et al.   SEMINARS IN CANCER BIOLOGY

Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results

(2019) Thilo Gambichler et al.   OncoImmunology

Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets

(2019) Maria Sofia Basile et al.   Frontiers in Oncology

BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients

(2019) Emi Dika et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Primary and Metastatic Melanoma With NTRK Fusions

(2018) Cecilia Lezcano et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Whole-exome sequencing of a meningeal melanocytic tumour reveals activating CYSLTR2 and EIF1AX hotspot mutations and similarities to uveal melanoma

(2018) Heidi V. N. Küsters-Vandevelde et al.   Brain Tumor Pathology

Spitzoid melanoma with histopathologic features of ALK gene rearrangement exhibiting ALK copy number gain: A novel mechanism of ALK activation in spitzoid neoplasia

(2018) M. Farah et al.   BRITISH JOURNAL OF DERMATOLOGY

MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients

(2018) Michael Constantin Kirchberger et al.   EUROPEAN JOURNAL OF CANCER

The Immune Landscape of Cancer

(2018) Vésteinn Thorsson et al.   IMMUNITY

Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)

(2018) Richard D. Carvajal et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetic Alterations in Primary Acral Melanoma and Acral Melanocytic Nevus in Korea: Common Mutated Genes Show Distinct Cytomorphological Features

(2018) Ki Rang Moon et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network

(2018) Julie Delyon et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Pembrolizumab for primary malignant melanoma of the central nervous system

(2018) Chakib El Habnouni et al.   JOURNAL OF NEURO-ONCOLOGY

Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets

(2018) Jiong Lyu et al.   JOURNAL OF PATHOLOGY

TERT copy gain predicts the outcome of high-dose interferon α-2b therapy in acral melanoma

(2018) Sifan Yu et al.   OncoTargets and Therapy

Analysis of KIT gene mutations in patients with melanoma of the head and neck mucosa: a retrospective clinical report

(2018) Ullyanov Bezerra Toscano de Mendonça et al.   Oncotarget

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

(2018) Omid Hamid et al.   BRITISH JOURNAL OF CANCER

Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: Overall survival findings.

(2018) Takami Sato et al.   JOURNAL OF CLINICAL ONCOLOGY

High response rate to PD-1 blockade in desmoplastic melanomas

(2018) Zeynep Eroglu et al.   NATURE

The Cancer Genome Atlas Project: An Integrated Molecular View of Uveal Melanoma

(2018) Martine J. Jager et al.   OPHTHALMOLOGY

An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules

(2018) Jane Harper et al.   PLoS One

Melanoma subtypes: Genomic profiles, prognostic molecular markers and therapeutic possibilities

(2018) Roy Rabbie et al.   JOURNAL OF PATHOLOGY

Tumor mutational burden and response to PD-1 inhibitors in a case series of patients with metastatic desmoplastic melanoma

(2018) Lise Boussemart et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Human tumor genomics and zebrafish modeling identify SPRED1 loss as a driver of mucosal melanoma

(2018) Julien Ablain et al.   SCIENCE

Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma

(2018) Claire Mignard et al.   Journal of Oncology

Amelanotic Meningeal Melanoma with Leptomeningeal Dissemination: A Case Report and Systematic Literature Review

(2018) Simin Zhang et al.   World Neurosurgery

PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma

(2017) Asad Javed et al.   Immunotherapy

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

(2017) Sandra P. D’Angelo et al.   JOURNAL OF CLINICAL ONCOLOGY

Landscape of genomic alterations (GA) and tumor mutational burden (TMB) in different metastatic melanoma (MM) subtypes.

(2017) Douglas Buckner Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Mucosal melanoma: clinical, histological and c-kit gene mutational profile of 86 French cases

(2017) E. Cinotti et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

The NF1 gene in tumor syndromes and melanoma

(2017) Maija Kiuru et al.   LABORATORY INVESTIGATION

Melanoma subtypes demonstrate distinct PD-L1 expression profiles

(2017) Genevieve J Kaunitz et al.   LABORATORY INVESTIGATION

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

(2017) Jacob Schachter et al.   LANCET

Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

(2017) Reinhard Dummer et al.   LANCET ONCOLOGY

Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma

(2017) Jennifer D. Hintzsche et al.   MELANOMA RESEARCH

Spitz nevi and Spitzoid melanomas: exome sequencing and comparison with conventional melanocytic nevi and melanomas

(2017) Rossitza Lazova et al.   MODERN PATHOLOGY

NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics

(2017) Helena Cirenajwis et al.   Molecular Oncology

Whole-genome landscapes of major melanoma subtypes

(2017) Nicholas K. Hayward et al.   NATURE

Primary central nervous system malignant melanoma with leptomeningeal melanomatosis: a case report and review of the literature

(2017) Kentaro Fujimori et al.   NEUROSURGICAL REVIEW

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

(2017) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition

(2017) H S Kim et al.   ONCOGENE

BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases

(2017) Şule Öztürk Sari et al.   PATHOLOGY

Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma

(2017) Alain P. Algazi et al.   Pigment Cell & Melanoma Research

Kinase gene fusions in defined subsets of melanoma

(2017) Jacqueline Turner et al.   Pigment Cell & Melanoma Research

Molecular genetic and immunotherapeutic targets in metastatic melanoma

(2017) C. Melis et al.   VIRCHOWS ARCHIV

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

(2017) Ryan J. Sullivan et al.   Cancer Discovery

Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations

(2017) Ioana Cosgarea et al.   Oncotarget

Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines

(2017) Bradley Garman et al.   Cell Reports

Association of Incident Amelanotic Melanoma With Phenotypic Characteristics, MC1R Status, and Prior Amelanotic Melanoma

(2017) Steven Vernali et al.   JAMA Dermatology

Mucosal Melanoma: A Clinically and Biologically Unique Disease Entity

(2017) Richard D. Carvajal et al.   Journal of the National Comprehensive Cancer Network

Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation

(2016) Klaus J. Busam et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Pimasertib (PIM) versus dacarbazine (DTIC) in patients (pts) with cutaneous NRAS melanoma: a controlled, open-label phase II trial with crossover

(2016) C. Lebbe et al.   ANNALS OF ONCOLOGY

Primary Noncutaneous Malignant Melanoma of the Breast

(2016) Mohammad Rassouli et al.   Breast Journal

The efficacy of anti-PD-1 agents in acral and mucosal melanoma

(2016) Alexander N. Shoushtari et al.   CANCER

GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis

(2016) Xinan Sheng et al.   EUROPEAN JOURNAL OF CANCER

GermlineBAP1alterations in familial uveal melanoma

(2016) Karan Rai et al.   GENES CHROMOSOMES & CANCER

NCCN Guidelines Insights: Melanoma, Version 3.2016

(2016) Daniel G. Coit et al.   Journal of the National Comprehensive Cancer Network

Melanoma masquerading as nonmelanocytic lesions

(2016) Audrey Detrixhe et al.   MELANOMA RESEARCH

Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma

(2016) Amanda R Moore et al.   NATURE GENETICS

Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis

(2016) Deborah Kuk et al.   ONCOLOGIST

Uveal Melanomas with SF3B1 Mutations

(2016) Serdar Yavuzyigitoglu et al.   OPHTHALMOLOGY

Characteristics and Surgical Outcomes for Primary Malignant Melanoma of the Esophagus

(2016) Shugeng Gao et al.   Scientific Reports

Driver Mutations in Uveal Melanoma

(2016) Christina L. Decatur et al.   JAMA Ophthalmology

18F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis

(2015) Powell Perng et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

NF1 Mutations Are Common in Desmoplastic Melanoma

(2015) Thomas Wiesner et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Primary dermal melanoma: a West Australian cohort

(2015) James Teow et al.   ANZ JOURNAL OF SURGERY

Genomic Classification of Cutaneous Melanoma

(2015) Rehan Akbani et al.   CELL

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

(2015) R. D. Carvajal et al.   CLINICAL CANCER RESEARCH

VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors

(2015) Thibault Voron et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mutation scanning ofBRAF,NRAS,KIT,andGNAQ/GNA11in oral mucosal melanoma: a study of 57 cases

(2015) Jiong Lyu et al.   JOURNAL OF ORAL PATHOLOGY & MEDICINE

Metastatic melanomas of unknown primary show better prognosis than those of known primary: A systematic review and meta-analysis of observational studies

(2015) Jung Min Bae et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

(2015) Alexander M M Eggermont et al.   LANCET ONCOLOGY

A phase 2 study of tremelimumab in patients with advanced uveal melanoma

(2015) Anthony M. Joshua et al.   MELANOMA RESEARCH

Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway

(2015) A Hunter Shain et al.   NATURE GENETICS

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review

(2015) D. B. Johnson et al.   ONCOLOGIST

Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06)

(2015) S. J. Lee et al.   ONCOLOGIST

Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

(2015) Lisa Zimmer et al.   PLoS One

Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies

(2015) D. B. Johnson et al.   Cancer Immunology Research

Molecular Characterization and Patient Outcome of Melanoma Nodal Metastases and an Unknown Primary Site

(2014) Aleksandra Gos et al.   ANNALS OF SURGICAL ONCOLOGY

Hippo-Independent Activation of YAP by the GNAQ Uveal Melanoma Oncogene through a Trio-Regulated Rho GTPase Signaling Circuitry

(2014) Xiaodong Feng et al.   CANCER CELL

Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma

(2014) Richard D. Carvajal et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Update on primary mucosal melanoma

(2014) Joselin D. Tacastacas et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Atypical Spitz tumours and sentinel lymph node biopsy: a systematic review

(2014) Aimilios Lallas et al.   LANCET ONCOLOGY

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

(2014) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Primary malignant melanoma of the breast: A case report and review of the literature

(2014) YUJUN HE et al.   Oncology Letters

Kinase fusions are frequent in Spitz tumours and spitzoid melanomas

(2014) Thomas Wiesner et al.   Nature Communications

Comparison of Clinicopathologic Features and Survival of Histopathologically Amelanotic and Pigmented Melanomas

(2014) Nancy E. Thomas et al.   JAMA Dermatology

SOX10 Expression Distinguishes Desmoplastic Melanoma From Its Histologic Mimics

(2013) Beth Palla et al.   AMERICAN JOURNAL OF DERMATOPATHOLOGY

Clinical activity of ipilimumab for metastatic uveal melanoma

(2013) Jason J. Luke et al.   CANCER

Phase II Randomized Trial Comparing High-Dose IFN- 2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma

(2013) B. Lian et al.   CLINICAL CANCER RESEARCH

Characterization of KIT mutation in melanoma

(2013) Chi-Yuan Tzen et al.   Dermatologica Sinica

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma

(2013) Michele Del Vecchio et al.   EUROPEAN JOURNAL OF CANCER

Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

(2013) F. Stephen Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY

Phenotypic Characterization of Nevus and Tumor Patterns in MITF E318K Mutation Carrier Melanoma Patients

(2013) Richard A. Sturm et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma

(2013) Simon J Furney et al.   JOURNAL OF PATHOLOGY

The Liverpool uveal melanoma liver metastases pathway: Outcome following liver resection

(2013) D. Gomez et al.   JOURNAL OF SURGICAL ONCOLOGY

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

(2013) Paolo A Ascierto et al.   LANCET ONCOLOGY

Characteristics and survival of patients with invasive amelanotic melanoma in the USA

(2013) Jacqueline F. Moreau et al.   MELANOMA RESEARCH

BRAF and KIT somatic mutations are present in amelanotic melanoma

(2013) Daniela Massi et al.   MELANOMA RESEARCH

Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3

(2013) Marcel Martin et al.   NATURE GENETICS

Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma

(2013) J William Harbour et al.   NATURE GENETICS

Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations

(2013) X Chen et al.   ONCOGENE

Ipilimumab for Patients With Advanced Mucosal Melanoma

(2013) M. A. Postow et al.   ONCOLOGIST

Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas

(2013) Hai-Tao Niu et al.   Pigment Cell & Melanoma Research

SF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma

(2013) S. J. Furney et al.   Cancer Discovery

Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab

(2012) Vafa Shahabi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Uveal melanoma

(2012) Francesco Spagnolo et al.   CANCER TREATMENT REVIEWS

Sunitinib Therapy for Melanoma Patients withKITMutations

(2012) David R. Minor et al.   CLINICAL CANCER RESEARCH

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

(2012) A. M. Menzies et al.   CLINICAL CANCER RESEARCH

BRAF inhibitor activity in V600R metastatic melanoma

(2012) Oliver Klein et al.   EUROPEAN JOURNAL OF CANCER

Amelanotic melanomas presenting as red skin lesions: a diagnostic challenge with potentially lethal consequences

(2012) Susannah E. McClain et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Iris melanoma: Features and prognosis in 317 children and adults

(2012) Carol L. Shields et al.   JOURNAL OF AAPOS

Desmoplastic melanoma: A review

(2012) Lucy L. Chen et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET ONCOLOGY

The role of 8q24 copy number gains and c-MYC expression in amelanotic cutaneous melanoma

(2012) Pedram Pouryazdanparast et al.   MODERN PATHOLOGY

Detection and Time to Treatment of Uveal Melanoma in the United Kingdom: An Evaluation of 2384 Patients

(2012) Erika M. Damato et al.   OPHTHALMOLOGY

The genetics of uveal melanoma: an emerging framework for targeted therapy

(2012) J. William Harbour   Pigment Cell & Melanoma Research

Sphincter-sparing local excision and hypofractionated radiation therapy for anorectal melanoma

(2011) Patrick Kelly et al.   CANCER

NRAS mutation status is an independent prognostic factor in metastatic melanoma

(2011) John A. Jakob et al.   CANCER

KIT Pathway Alterations in Mucosal Melanomas of the Vulva and Other Sites

(2011) K. Omholt et al.   CLINICAL CANCER RESEARCH

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

(2011) J. M. Kirkwood et al.   CLINICAL CANCER RESEARCH

Nilotinib in patients with metastatic melanoma harboring KIT gene aberration

(2011) Jin Hyun Cho et al.   INVESTIGATIONAL NEW DRUGS

KIT as a Therapeutic Target in Metastatic Melanoma

(2011) Richard D. Carvajal   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification

(2011) Jun Guo et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma

(2011) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Amelanotic melanoma: a detailed morphologic analysis with clinicopathologic correlation of 75 cases

(2011) Wang L. Cheung et al.   JOURNAL OF CUTANEOUS PATHOLOGY

Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma

(2011) Bianca Devitt et al.   Pigment Cell & Melanoma Research

Utility of Lymph Node Assessment for Atypical Spitzoid Melanocytic Neoplasms

(2010) Bahair Ghazi et al.   ANNALS OF SURGICAL ONCOLOGY

Targeting KIT in melanoma: A paradigm of molecular medicine and targeted therapeutics

(2010) Scott E. Woodman et al.   BIOCHEMICAL PHARMACOLOGY

Mutations inGNA11in Uveal Melanoma

(2010) Catherine D. Van Raamsdonk et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure

(2010) Despina Handolias et al.   Pigment Cell & Melanoma Research

Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas

(2010) J. W. Harbour et al.   SCIENCE

CDKN2A and MC1R analysis in amelanotic and pigmented melanoma

(2009) Paola Ghiorzo et al.   MELANOMA RESEARCH

Primary Dermal Melanoma

(2008) David S. Cassarino et al.   ARCHIVES OF DERMATOLOGY

Phase II trial of imatinib mesylate in patients with metastatic melanoma

(2008) K B Kim et al.   BRITISH JOURNAL OF CANCER

KIT Gene Mutations and Copy Number in Melanoma Subtypes

(2008) C. Beadling et al.   CLINICAL CANCER RESEARCH

“White” Nevi and “Red” Melanomas: Association with the RHC Phenotype of the MC1R Gene

(2008) Iris Zalaudek et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

(2008) Catherine D. Van Raamsdonk et al.   NATURE